Kiromic BioPharma's Deltacel-01 Clinical Trial Displays Promising Results

New Findings from Kiromic BioPharma's Clinical Trial

Kiromic BioPharma, Inc. (OTCQB: KRBP) is making waves in the clinical research community with promising results from the ongoing Deltacel-01 Phase 1 clinical trial. This study focuses on Deltacel (KB-GDT-01), a groundbreaking allogeneic gamma delta T-cell therapy targeted at patients battling stage 4 metastatic non-small cell lung cancer (NSCLC), particularly those who have not seen success with standard treatments.

Significant Improvements in Patient Outcomes

The first patient enrolled in this trial experienced notable progress, with a tumor size reduction of around 27% compared to pre-treatment evaluations. Impressively, there were no new disease sites identified, leading to an extended progression-free survival rate of 10 months without any adverse events reported. This patient had previously shown a tumor size decrease of approximately 20% at the eight-month follow-up and 13% reduction at six months, indicating a positive trend and sustained efficacy of the treatment.

Comments from the Kiromic Team

Pietro Bersani, the Chief Executive Officer of Kiromic BioPharma, shared his excitement over these latest results, remarking, "We are particularly encouraged by these findings, which reinforce the potential of Deltacel as both a safe and effective option for late-stage cancer patients." This sentiment is echoed by Dr. Afshin Eli Gabayan, a medical oncologist and the principal investigator for the trial, who noted that such responses to gamma delta T-cell therapy could represent a vital advancement in available options for those facing limited treatment pathways.

The Deltacel-01 Clinical Trial Explained

The Deltacel-01 trial is an open-label Phase 1 study that focuses on evaluating the safety and tolerability of gamma delta T cell infusions, combined with low-dose radiotherapy, for patients with advanced NSCLC. Participants in this study will receive two intravenous infusions of Deltacel within a 10-day period, alongside localized radiation therapy sessions. The primary focus of the trial is safety, while researchers are also keen to measure other important factors such as objective response rates and overall survival.

Understanding Deltacel (KB-GDT-01)

Deltacel (KB-GDT-01) itself is an innovative therapy that harnesses the power of gamma delta T-cells to potentially target solid tumors more effectively. As an allogeneic product derived from donor cells, it stands as a leader in Kiromic’s platform aimed at advancing treatment options in immuno-oncology. Initial clinical interests center on NSCLC, which accounts for a significant percentage of lung cancer diagnoses.

A Look at the Beverly Hills Cancer Center

The clinical trials are being conducted at the Beverly Hills Cancer Center, a respected private institution that specializes in providing cutting-edge cancer care. Their comprehensive approach allows them to run leading clinical trials while also giving patients access to some of the most advanced treatment options in development. The talented team at BHCC includes experts from various medical disciplines, ensuring patients receive holistic care and support throughout their treatment journey.

Future Directions for Kiromic BioPharma

Kiromic BioPharma is enthusiastic about sharing further follow-up results from additional patients enrolled in the Deltacel-01 trial in the near future. With ongoing evaluations and analyses, they aim to continue uncovering the therapeutic potential that Deltacel holds in revolutionizing treatments for stage 4 lung cancer and possibly beyond.

Frequently Asked Questions

What is Deltacel-01?

Deltacel-01 is a Phase 1 clinical trial evaluating the safety and efficacy of Deltacel, a gamma delta T-cell therapy, for stage 4 metastatic NSCLC.

What were the results for the first patient treated?

The first patient seen in the trial experienced a 27% tumor size reduction and has had a progression-free survival period of 10 months with no reported adverse events.

Where is the trial being conducted?

The Deltacel-01 trial is taking place at the Beverly Hills Cancer Center, known for its advanced cancer treatments and clinical trials.

What is the primary goal of the Deltacel-01 trial?

The main objective of the Deltacel-01 trial is to assess the safety and tolerability of Deltacel therapy combined with low-dose radiotherapy.

What is the significance of the trial for late-stage lung cancer patients?

The trial aims to provide potential new treatment options for late-stage lung cancer patients who have limited therapeutic alternatives, offering hope through innovative therapies like Deltacel.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.